Larimar Therapeutics, Inc. (ZA71.F)
Frankfurt · EUR · Healthcare · Biotechnology
€2.10 (+8.25%) as of
Key statistics
- Market cap
- 218.15M
- EPS (TTM)
- -1.7100
- Dividend yield
- 0.00%
- 52-week range
- 1.7400 – 5.2500
- Beta
- 0.69
- Profit margin
- 0.00%
- Volume
- 1.00k
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bala Cynwyd, PA, United States
- Employees
- 71
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.